Author

Kousuke Onoue

Observed name: Onoue Kousuke

Institution: NEC (Japan)

Observed institution: NEC (Japan)

OpenAlex ID: A5088432030

Single-cell sequencing on CD8+ TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer/testis antigen in non-small cell lung cancer

2023 · Hiroyasu Komuro, Shuichi Shinohara, et al. · Journal for ImmunoTherapy of Cancer · 42

Candidate tumor-specific CD8 + T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis

2024 · Yusuke Sugita, Daisuke Muraoka, et al. · OncoImmunology · 13

Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma.

2023 · Christian H.H. Ottensmeier, Jean-Pierre Delord, et al. · Journal of Clinical Oncology · 11

Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).

2022 · Jean-Pierre Delord, Matthew Stephen Block, et al. · Journal of Clinical Oncology · 9

650 Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)

2024 · Christophe Le Tourneau, Jean-Pierre Delord, et al. · Regular and Young Investigator Award Abstracts · 1

Abstract LB205: Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer

2023 · Ana Lalanne, Camille Jamet, et al. · Cancer Research · 1

Abstract CT182: Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients

2022 · Matthew S. Block, Jean-Pierre Delord, et al. · Cancer Research · 1

Abstract 4566: Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine

2020 · Brandon Malone, Caroline Tosch, et al. · Cancer Research · 1

Works count: 8

Citation count: 79

H-index: 4

I10-index: 3